Welcome to LookChem.com Sign In|Join Free
  • or
2-[(E)-(quinolin-3-ylimino)methyl]phenol is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

129855-32-9

Post Buying Request

129855-32-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

129855-32-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 129855-32-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,9,8,5 and 5 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 129855-32:
(8*1)+(7*2)+(6*9)+(5*8)+(4*5)+(3*5)+(2*3)+(1*2)=159
159 % 10 = 9
So 129855-32-9 is a valid CAS Registry Number.

129855-32-9Downstream Products

129855-32-9Relevant academic research and scientific papers

Synthesis, characterization and distinct butyrylcholinesterase activities of transition metal complexes of 2-[(E)-(quinolin-3-ylimino)methyl]phenol

Ikram, Muhammad,Saeed-Ur-Rehman,Rehman, Sadia,Baker, Robert J.,Schulzke, Carola

, p. 210 - 216 (2012)

2-[(E)-(Quinolin-3-ylimino)methyl]phenol (H-QMP) was synthesized by condensing salicylaldehyde with 2-aminoquinoline and fully characterized by mass spectrometry, 1H and 13C{1H}NMR, and IR spectroscopies. The metal complex

Development of novel ruthenium(ii)-arene complexes displaying potent anticancer effects in glioblastoma cells

Kulshreshtha, Ritu,Kumar, Priyaranjan,Mondal, Indranil,Patra, Ashis K.

, p. 13294 - 13310 (2020)

Glioblastomas (GBs) are highly aggressive and malignant brain tumors, which are highly resistant to conventional multimodal treatments, leading to their abysmal prognosis. Herein, we designed two organometallic half-sandwich Ru(ii)-η6-p-cymene complexes containing Schiff bases derived from 3-aminoquinoline and 2-hydroxy-benzaldehyde (L1) and 2-hydroxy-naphthaldehyde (L2), namely [Ru(η6-p-cymene)(L1)Cl] (1) and [Ru(η6-p-cymene)(L2)Cl] (2), respectively, and studied their activity on GB cells. Both complexes were structurally characterized using single-crystal X-ray diffraction, which exhibited their half-sandwich three-legged piano-stool geometry. Furthermore, we studied their physicochemical behavior, solution speciation, aquation kinetics, and photo-substitution reactions using various spectroscopic methods. The complexes exhibited a moderate binding affinity with calf-thymus (CT)-DNA (Kb~ 105M?1). The complexes effectively interacted with human serum albumin (HSA) (K~ 105M?1) with preferential tryptophan binding, as determinedviasynchronous fluorescence studies. Thein vitrostudies showed their significant antiproliferative activity against an aggressive human GB cell line, LN-229 (IC50= 22.8 μM), with moderate selectivity relative to normal mouse fibroblast L929 cells. Notably, [Ru(η6-p-cymene)(L1)Cl] (1) exhibited a higher selectivity index (S.I.) than [Ru(η6-p-cymene)(L2)Cl] (2) and cisplatin. We evaluated the clonogenic potential of the GB cells using a colony formation assay in the presence of complex1. Excitingly, it showed ~75% inhibition of the clonogenic potential of GB cells at the IC50concentration. Complex1also effectively lowered the migratory potential of the GB cells, as assessed by the wound healing assay. The studied compound led to the apoptosis of GB cells, as evidenced by nuclear condensation, blebbing, and enhanced caspase 3/7 activity, and thus has anticipated utility in the treatment of GBs using photochemotherapy.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 129855-32-9